Although the traditional approach to identifying cancer-causing genetic alterations and interactions has been focused on single genes or proteins, we increasingly recognize that alterations of biological processes involve coordinated changes in the expression of dozens or hundreds of genes, or in the activity of multiple signaling pathways. With the availability of the complete sequence of the human and mouse genomes, experimentalists can now use global approaches that simultaneously examine multitudes of genes at once. In addition, the ability to collect these rich data from clinical specimens using automated analysis of images, or proteomic approaches to the kinome, is also rapidly growing. These developments necessitate the integration of genetics, genomics and proteomics, with pathology and clinical oncology research. To manage and analyze these complex datasets, translational researchers must be facile with bioinformatics, statistics, and biostatistics. In response to these needs, the UNC Breast SPORE has developed Core B, the Genomics, Biostatistics, and Bioinformatics shared resource. Under the experienced leadership of the SPORE Co-PI Charles Perou (Genetics), Dr. Joe Ibrahim (Biostatistics) and Dr. Steve Marron (Statistics), Core B brings together under one roof three critical services - Genomic assays (DNA microarrays, mRNA- sequencing and gene expression profiling using FFPE RNA and the Nanostring platform), a robust Bioinformatics computing environment, and expertise in Biostatistics and Statistics - and focuses these resources on translational breast cancer research. All proposed SPORE Projects (1-5) will work with Core B. The Core B services are tunneled into this core through three UNC Lineberger Comprehensive Cancer Center (LCCC) shared resources - namely the Genomics Core Facility, the Bioinformatics Core, and the Biostatistics Core. In all of these LCCC Cores, the studies of Breast SPORE investigators have spurred the development of methods and equipment upgrades that have benefited and stimulated other Cancer Center research. By supporting key personnel in these LCCC Cores, the UNC Breast SPORE is assuring priority service and performance. Dr. Perou's expertise and experience with these services, and his leadership of the Cancer Center's Genomics &Bioinformatics Cores, together with Dr. Marron and Dr. Ibrahim's experience as the LCCC Biostatistics Core leader, means that Core B is integral to this Breast SPORE, integrated into the Cancer Center structure, and poised to provide priority services for Breast SPORE investigators.

Public Health Relevance

Cancer biology and clinical medicine are becoming more and more dependent upon the analysis of complex and large datasets, which are often based upon genomic and/or proteomic data accompanied by pathological and clinical data. The coordinated analysis of these multiple data types requires a highly sophisticated, facile, and rigorous bioinformatics and statistical infrastructure. This Core brings together all the needed expertise and tools for these computational challenges so that advances in breast cancer treatment can be made.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-20
Application #
8547141
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
20
Fiscal Year
2013
Total Cost
$147,915
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Butler, Eboneé N; Bensen, Jeannette T; Chen, Mengjie et al. (2018) Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors. Cancer Epidemiol Biomarkers Prev 27:67-74
Echavarria, Isabel; López-Tarruella, Sara; Picornell, Antoni et al. (2018) Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res 24:1845-1852
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45

Showing the most recent 10 out of 598 publications